Core Viewpoint - The company, Blue Biological (603739), has received approval from the Ministry of Agriculture and Rural Affairs for its new veterinary drug, "Oxidized Amine Iodine Solution," which is classified as a Class III new veterinary drug and is intended for disinfection in farming environments [1] Group 1 - The approval includes a registration certificate for the new veterinary drug [1] - The new product is developed in collaboration with the company's wholly-owned subsidiary, Qingdao Kangdian Animal Pharmaceutical Co., Ltd., and other units [1]

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-055 青岛蔚蓝生物股份有限公司 关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》等的相关规定，经农业农村部审 查，批准青岛蔚蓝生物股份有限公司（以下简称"公司"）及全资子公司青岛康 地恩动物药业有限公司与其他单位联合申报的"氧化胺碘溶液"为三类新兽药， 并于近日核发了《新兽药注册证书》（农业农村部公告第 970 号）。 新兽药名称：氧化胺碘溶液 研制单位：青岛农业大学、青岛蔚蓝生物股份有限公司、云南农业大学、四 川瑞芳德生物制药有限责任公司、成都科宏达科技有限公司、青岛康地恩动物药 业有限公司、山东康益健生物科技有限公司、河北金元康药业有限公司、大理金 明动物药业有限公司、青岛元成生物科技有限公司、安徽中龙国创生物科技有限 公司、江西派尼生物药业有限公司、济南百鸣生物制药有限公司、海南育奇药业 有限公司。 主要成分：碘 作用与用途：用于厩舍的消毒。 用法与用量：以本品计。喷雾：厩舍地面、墙面、食槽的 ...

Core Viewpoint - The company, Blue Biological (603739), has received approval for its new veterinary drug "Oxytetracycline Iodine Solution" as a Class III new veterinary drug, with the issuance of the "New Veterinary Drug Registration Certificate" [1] Group 1 - The company and its wholly-owned subsidiary, Qingdao Kangdian Animal Pharmaceutical Co., Ltd., jointly applied for the approval of the new veterinary drug [1] - The approval signifies a significant milestone for the company in expanding its product offerings in the veterinary medicine sector [1]

Core Viewpoint - The company, Weilan Bio (603739.SH), has received approval from the Ministry of Agriculture and Rural Affairs for its new veterinary drug, "Oxidized Amine Iodine Solution," which is classified as a Class III new veterinary drug and is intended for disinfection in breeding environments [1]. Group 1 - The approval was granted based on the review of relevant regulations, including the "Veterinary Drug Management Regulations" and the "Veterinary Drug Registration Measures" [1]. - The new veterinary drug registration certificate was issued recently, as indicated by the Ministry of Agriculture and Rural Affairs announcement No. 970 [1]. - The product is developed by the company and its wholly-owned subsidiary, Qingdao Kangdian Animal Pharmaceutical Co., Ltd., in collaboration with other entities [1].

Core Viewpoint - The company, Blue Biological (603739.SH), announced that its wholly-owned subsidiary, Qingdao Kangdian Animal Pharmaceutical Co., Ltd., along with other units, has received approval for "Oxytetracycline Iodine Solution" as a Class III new veterinary drug, and has recently been issued a "New Veterinary Drug Registration Certificate" [1] Company Summary - Blue Biological has successfully obtained regulatory approval for a new veterinary drug, indicating progress in its product development pipeline [1] - The approval of the new veterinary drug may enhance the company's market position and expand its product offerings in the veterinary pharmaceutical sector [1] Industry Summary - The approval of new veterinary drugs is significant for the industry, as it reflects ongoing innovation and regulatory compliance within the veterinary pharmaceutical market [1] - The introduction of Class III new veterinary drugs can potentially lead to increased competition and improved animal health solutions in the market [1]

Core Viewpoint - The company is actively expanding its pet health product line, with a long-term product planning scheme that includes chemical drugs, biological products, and pet health products [1] Group 1: Product Development - The company is focusing on self-branded production and sales of pet health products, without engaging in OEM business [1] - A comprehensive R&D and market operation team will be gradually established to support product promotion [1] Group 2: Market Strategy - The company plans to develop distribution channels primarily through offline veterinary hospitals [1] - The company will adhere to the disclosure obligations as per the Shanghai Stock Exchange regulations, ensuring timely announcements of relevant information [1]

Core Viewpoint - The company, Weilan Bio (603739), is currently in the early stages of developing synthetic biology products, with significant challenges ahead in terms of commercialization and industrialization [1] Group 1: Research and Development - The company has established a synthetic biology and biocatalysis technology center, which includes an innovation laboratory focused on developing functional proteins for feed and sweeteners for food [1] - The current R&D projects in the synthetic biology technology innovation laboratory are limited, with low investment amounts and insufficient professional personnel [1] - The laboratory is still in the preliminary strain research phase, indicating a considerable gap before achieving large-scale production [1] Group 2: Production Challenges - The production of synthetic biology products involves complex processes such as separation and purification, which the company currently lacks the capability to perform [1] - There are significant uncertainties regarding the commercialization of these products, which may also require regulatory approvals and market promotion, leading to a lengthy and challenging process [1] Group 3: Impact on Operations - The company anticipates that the current developments in synthetic biology will not have a significant impact on its operations in the foreseeable future [1] - The company will adhere to the disclosure obligations as per the Shanghai Stock Exchange regulations and will provide timely updates through official announcements [1]

Core Viewpoint - The company currently has one synthetic biology and biocatalysis technology center, which includes a synthetic biology technology innovation laboratory focused on developing functional proteins for feed and sweeteners for food [1] Group 1 - The synthetic biology technology innovation laboratory is primarily used for research and development of functional proteins for animal feed and sweeteners for food [1] - The laboratory has a limited number of R&D projects, small investment amounts, and insufficient professional personnel, indicating it is still in the early stages of strain laboratory research [1] - There is a significant gap to scale-up production, and the laboratory does not currently meet industrialization conditions [1]

Core Viewpoint - The company, Weilan Bio (603739.SH), currently lacks the necessary production processes for synthetic biology products, which involve complex separation and purification techniques, indicating significant challenges in commercialization [1] Group 1 - The production of synthetic biology products requires advanced separation and purification processes, which the company does not currently possess [1] - The purification process is noted to be particularly difficult, suggesting a need for further development before the company can effectively produce these products [1] - Future production may also involve regulatory approvals, product selection, and market promotion, all of which are expected to have long cycles and significant challenges, leading to major uncertainties in commercialization [1] Group 2 - The company anticipates that these challenges will not have a significant impact on its operations in the near term [1]

Core Insights - The phytic acid enzyme market is experiencing significant growth, primarily driven by increased demand in the feed industry, especially after the ban on antibiotics in animal feed in China in 2020, positioning phytic acid enzymes as ideal alternatives [1][7] - China's annual production of phytic acid enzymes has significantly increased, from 43,200 tons in 2015 to an expected 120,600 tons by 2024, indicating a robust growth trajectory [1][8] - The global phytic acid enzyme market is projected to grow from $513 million in 2023 to $822 million by 2029, with a compound annual growth rate (CAGR) of 8.2% [6] Industry Overview - Phytic acid enzymes belong to the class of phosphoric monoester hydrolases and are crucial for enhancing the bioavailability of minerals in plant-based feeds by breaking down phytic acid [2] - The industry has evolved through three stages: initial development in the 1990s, rapid growth from 2001 to 2012, and a mature phase from 2013 onwards, with domestic products replacing imports and achieving international technical standards [3][4] Industry Chain - The upstream of the phytic acid enzyme industry includes raw materials such as wheat, barley, and microorganisms, while the downstream applications span food, pharmaceutical, and feed industries [5] - The feed industry is the largest application area for phytic acid enzymes, driven by the need to improve feed efficiency and reduce costs, with a notable increase in China's feed production reaching 250.7 million tons in the first nine months of 2025, up 6.4% year-on-year [5][6] Competitive Landscape - The global phytic acid enzyme market is highly competitive, with companies like Novozymes, DuPont, and DSM holding significant market shares due to their technological advantages and patent protections [8] - Chinese companies such as Blue Horizon Biotechnology, Yidali, and Xinghuo Technology are emerging as strong competitors, gradually capturing high-end market segments [8] Development Trends - Technological innovation is a key driver for the industry, with advancements in enzyme production and purification methods expected to enhance yield and efficiency [10] - The application of phytic acid enzymes is expanding beyond traditional uses in poultry and pig feed to include aquaculture and organic agriculture, indicating new growth opportunities [11] - Environmental sustainability is becoming increasingly important, with stricter regulations prompting phytic acid enzyme companies to enhance their eco-friendly practices and production processes [12]